Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib.
Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, Russo A, Caraglia M. Stiuso P, et al. Among authors: prete sd. Mol Ther Nucleic Acids. 2015 Mar 17;4:e233. doi: 10.1038/mtna.2015.8. Mol Ther Nucleic Acids. 2015. PMID: 25782064 Free article.
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases.
Addeo R, Sperlongano P, Montella L, Vincenzi B, Carraturo M, Iodice P, Russo P, Parlato C, Salzano A, Cennamo G, Lombardi A, Sperlongano R, Prete SD, Caraglia M. Addeo R, et al. Among authors: prete sd. Cancer Chemother Pharmacol. 2012 Oct;70(4):603-9. doi: 10.1007/s00280-012-1945-4. Epub 2012 Aug 14. Cancer Chemother Pharmacol. 2012. PMID: 22890892
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R. Prete SD, et al. Cancer Chemother Pharmacol. 2010 Oct;66(5):837-44. doi: 10.1007/s00280-009-1226-z. Epub 2009 Dec 30. Cancer Chemother Pharmacol. 2010. PMID: 20041325 Clinical Trial.
The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P, Budillon A, Venuta S, Abbruzzese A. Caraglia M, et al. Among authors: prete sd. Oncogene. 2004 Sep 9;23(41):6900-13. doi: 10.1038/sj.onc.1207814. Oncogene. 2004. PMID: 15286715
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Correale P, Messinese S, Caraglia M, Marsili S, Piccolomini A, Petrioli R, Ceciarini F, Micheli L, Nencini C, Neri A, Vuolo G, Guarnieri A, Abbruzzese A, Prete SD, Giorgi G, Francini G. Correale P, et al. Among authors: prete sd. Br J Cancer. 2004 May 4;90(9):1710-4. doi: 10.1038/sj.bjc.6601783. Br J Cancer. 2004. PMID: 15150625 Free PMC article. Clinical Trial.
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).
Orlando L, Lorusso V, Giotta F, Di Maio M, Schiavone P, Fedele P, Quaranta A, Caliolo C, Ciccarese M, Cinefra M, Romito S, Pisconti S, Prete SD, Aieta M, Rizzi D, Maiello E, Colucci G, Cinieri S. Orlando L, et al. Among authors: prete sd. Breast. 2020 Oct;53:18-22. doi: 10.1016/j.breast.2020.06.002. Epub 2020 Jun 5. Breast. 2020. PMID: 32540553 Free PMC article. Clinical Trial.
15 results